Halozyme Therapeutics, Inc. (HALO)

NASDAQ: HALO · IEX Real-Time Price · USD
40.68
-0.05 (-0.12%)
At close: Mar 28, 2024, 4:00 PM
40.87
+0.19 (0.47%)
After-hours: Mar 28, 2024, 7:57 PM EDT

Company Description

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.

The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.

The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma.

In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis.

Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.

Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Halozyme Therapeutics, Inc.
Halozyme Therapeutics logo
Country United States
Founded 1998
Industry Biotechnology
Sector Healthcare
Employees 373
CEO Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.

Contact Details

Address:
12390 El Camino Real
San Diego, California 92130
United States
Phone (858) 794-8889
Website halozyme.com

Stock Details

Ticker Symbol HALO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001159036
CUSIP Number 40637H109
ISIN Number US40637H1095
Employer ID 88-0488686
SIC Code 2836

Key Executives

Name Position
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. President, Chief Executive Officer and Director
Nicole LaBrosse Senior Vice President and Chief Financial Officer
Dr. Michael J. LaBarre Ph.D. Senior Vice President and Chief Technical Officer
Mark Snyder Esq. Senior Vice President and Chief Legal Officer
Cortney Caudill M.B.A. Chief Operations Officer
Tram Bui Head of Investor Relations and Corporate Communications
Amy Marinne Fox Chief Human Resources Officer
Dr. Steve Knowles MBBS Chief Medical Officer
Dr. Christopher Bryant Ph.D. Chief Manufacturing Officer and Head of Technical Operations
Kristin Schwartzbauer Head of Quality

Latest SEC Filings

Date Type Title
Mar 15, 2024 ARS Filing
Mar 15, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 15, 2024 DEF 14A Other definitive proxy statements
Mar 13, 2024 144 Filing
Mar 12, 2024 144 Filing
Mar 4, 2024 PRE 14A Other preliminary proxy statements
Feb 28, 2024 144 Filing
Feb 27, 2024 144 Filing
Feb 20, 2024 10-K Annual Report
Feb 20, 2024 8-K Current Report